Genmab — Juni 2018
-
virkelig!? Det lyder ikke som det stof blockbustere er lavet af
-
The latest FDA approval is based on data from a single cohort of a multi-cohort phase II study – KEYNOTE-158 – evaluating the drug in recurrent or metastatic cervical cancer. Data from a subset of patient population expressing PD-L1 with a CPS ≥1 showed that Keytruda achieved an objective response rate of 14.3%
-
-
vil man ikke kombinerer PD1'eren med evt. chemo? Det bringer vel ORR'en op?
-
Men solid er da vist et helt andet ball-game end hæmatologisk
-
men minimum 1,5 år til vi ser data fra det studie
-
-
Tre billige aktier - Åbent for spekulativ stigning i Genmab
Efter Genmabs kraftige kursfald i slutningen af maj ser kursen ud til at have stabiliseret sig omkring 950. På investorernes tillidsbarometer ligger Genmab stadig meget lavt med en score på 30 point ud af 100 mulige, men de oplysninger som sendte kursen ned bør nu være fuldt ud indarbejdet i kursen. Dermed er der åbnet […]
Økonomisk Ugebrev (ugebrev.dk)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind